IAPP抗体—艾普蒂 新品

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: HL-60 cell lysate, Primary antibody: P06847(IAPP Antibody) at dilution 1/600, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 2 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P06847(IAPP Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colorectal cancer tissue using P06847(IAPP Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

The islet amyloid polypeptide (IAPP), also known as amylin, is a hormone co-secreted with insulin by pancreatic β-cells. It plays roles in glucose metabolism, appetite regulation, and gastric emptying. In type 2 diabetes (T2D), misfolded IAPP aggregates into amyloid fibrils, contributing to β-cell dysfunction and apoptosis. These amyloid deposits, found in ~70% of T2D patients, are linked to disease progression and reduced insulin secretion.

IAPP antibodies are tools used to detect, quantify, and study the pathological role of IAPP in diabetes. They enable visualization of amyloid deposits in pancreatic tissues and help investigate mechanisms of β-cell toxicity. Recent research explores their therapeutic potential, such as targeting amyloid formation or enhancing clearance. Autoantibodies against IAPP have also been reported in some T2D cases, suggesting an autoimmune component.

While most studies focus on T2D, IAPP antibodies are also used in obesity and neurodegenerative disease research due to structural similarities between IAPP and Alzheimer’s-associated amyloid-β. Challenges remain in ensuring antibody specificity, as cross-reactivity with related peptides can occur. Ongoing work aims to refine these tools for diagnostic and therapeutic applications.